Find research datasets worth reusing

A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients

ClinicalTrials.gov study NCT01972438. IPD Sharing: NO. Countries: 1. Publications: 3.

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

ClinicalTrials.gov study NCT02065570. IPD Sharing: YES. Countries: 20. Publications: 6.

A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (H

ClinicalTrials.gov study NCT03842189. IPD Sharing: NO. Countries: 9. Publications: 2.

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov study NCT00510510. IPD Sharing: Not stated. Countries: 6. Publications: 1.

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov study NCT03345407. IPD Sharing: YES. Countries: 16. Publications: 1.

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

ClinicalTrials.gov study NCT04341116. IPD Sharing: NO. Countries: 1. Publications: 1.

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov study NCT01604278. IPD Sharing: Not stated. Countries: 10. Publications: 1.

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

ClinicalTrials.gov study NCT02766465. IPD Sharing: YES. Countries: 1. Publications: 3.

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

ClinicalTrials.gov study NCT05197049. IPD Sharing: YES. Countries: 27. Publications: 1.

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

ClinicalTrials.gov study NCT00358501. IPD Sharing: Not stated. Countries: 2. Publications: 2.

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)

ClinicalTrials.gov study NCT03559517. IPD Sharing: Not stated. Countries: 16. Publications: 1.

Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

ClinicalTrials.gov study NCT04713592. IPD Sharing: YES. Countries: 4. Publications: 0.

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov study NCT01350128. IPD Sharing: Not stated. Countries: 1. Publications: 1.

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

ClinicalTrials.gov study NCT00771667. IPD Sharing: Not stated. Countries: 12. Publications: 4.

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

ClinicalTrials.gov study NCT00363896. IPD Sharing: Not stated. Countries: 16. Publications: 1.

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

ClinicalTrials.gov study NCT05610280. IPD Sharing: YES. Countries: 14. Publications: 2.

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

ClinicalTrials.gov study NCT01369355. IPD Sharing: Not stated. Countries: 26. Publications: 16.

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheu

ClinicalTrials.gov study NCT00891020. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

ClinicalTrials.gov study NCT04502472. IPD Sharing: NO. Countries: 1. Publications: 15.

Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov study NCT01437540. IPD Sharing: Not stated. Countries: 1. Publications: 1.